

Status: Currently Official on 16-Feb-2025  
 Official Date: Official as of 01-Dec-2016  
 Document Type: USP Monographs  
 DocId: GUID-C72675E5-C90B-4CEF-958A-858F3A233E9D\_1\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M1397\\_01\\_01](https://doi.org/10.31003/USPNF_M1397_01_01)  
 DOI Ref: rv4ei

© 2025 USPC  
 Do not distribute

## Metoprolol Tartrate Compounded Oral Suspension

### DEFINITION

Metoprolol Tartrate Compounded Oral Suspension contains NLT 90.0% and NMT 110.0% of the labeled amount of metoprolol tartrate  $[(C_{15}H_{25}NO_3)_2 \cdot C_4H_6O_6]$ .

Prepare Metoprolol Tartrate Compounded Oral Suspension 10 mg/mL as follows (see [Pharmaceutical Compounding—Nonsterile Preparations \(795\)](#)).

Metoprolol Tartrate	1 g
Vehicle: a 1:1 mixture of Vehicle for Oral Solution, (regular or sugar-free), <i>NF</i> , and Vehicle for Oral Suspension, <i>NF</i> , a sufficient quantity to make	100 mL

Place the required number of tablets in a suitable mortar, and comminute to a fine powder, or use *Metoprolol Tartrate* powder. Add the *Vehicle* in small portions, and mix well. Transfer the contents of the mortar, stepwise and quantitatively, to a calibrated bottle. Add the *Vehicle* in portions to rinse the mortar. Add sufficient *Vehicle* to bring to final volume, and mix well.

### ASSAY

#### • PROCEDURE

**Mobile phase:** 961 mg of 1-pentanesulfonic acid sodium salt (monohydrate) and 82 mg of anhydrous sodium acetate in a mixture of 550 mL of methanol and 470 mL of water. Add 0.57 mL of glacial acetic acid. Filter, and degas.

**Standard solution:** 100  $\mu$ g/mL of [USP Metoprolol Tartrate RS](#)

**Sample solution:** Agitate the container of Oral Suspension for 30 min on a rotating mixer, remove a 5-mL sample, and store in a clear glass vial at  $-70^{\circ}$  until analyzed. At the time of analysis, remove the sample from the freezer, allow it to reach room temperature, and mix with a vortex mixer for 30 s. Pipet 1.0 mL of the sample to a 100-mL volumetric flask, and dilute with *Mobile phase* to volume.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 4.6-mm  $\times$  25-cm; 5- $\mu$ m packing L1

**Flow rate:** 1.0 mL/min

**Injection volume:** 20  $\mu$ L

#### System suitability

**Sample:** Standard solution

[NOTE—The retention time for metoprolol tartrate is about 7.3 min.]

#### Suitability requirements

**Relative standard deviation:** NMT 1.3% for replicate injections

#### Analysis

**Samples:** Standard solution and Sample solution

Calculate the percentage of the labeled amount of metoprolol tartrate  $[(C_{15}H_{25}NO_3)_2 \cdot C_4H_6O_6]$  in the portion of Oral Suspension taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

$r_u$  = peak response from the Sample solution

$r_s$  = peak response from the Standard solution

$C_S$  = concentration of [USP Metoprolol Tartrate RS](#) in the *Standard solution* ( $\mu\text{g}/\text{mL}$ )

$C_U$  = nominal concentration of metoprolol tartrate in the *Sample solution* ( $\mu\text{g}/\text{mL}$ )

**Acceptance criteria:** 90.0%–110.0%

#### SPECIFIC TESTS

- [pH \(791\)](#): 3.6–4.6

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Package in tight, light-resistant containers. Store at controlled room temperature, or in a refrigerator.
- **BEYOND-USE DATE:** NMT 60 days after the date on which it was compounded when stored at controlled room temperature, or in a refrigerator
- **LABELING:** Label it to state that it is to be well shaken, and to state the *Beyond-Use Date*.
- [USP REFERENCE STANDARDS \(11\)](#)

[USP Metoprolol Tartrate RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
METOPROLOL TARTRATE COMPOUNDED ORAL SUSPENSION	<a href="#">Brian Serumaga</a> Science Program Manager	CMP2020 Compounding 2020
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	CMP2020 Compounding 2020

**Chromatographic Database Information:** [Chromatographic Database](#)

#### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 40(6)

**Current DocID: GUID-C72675E5-C90B-4CEF-958A-858F3A233E9D\_1\_en-US**

**DOI:** [https://doi.org/10.31003/USPNF\\_M1397\\_01\\_01](https://doi.org/10.31003/USPNF_M1397_01_01)

**DOI ref:** [rv4ei](#)